From Mushroom to Active Compound: Psilocybin and Psilocin
Psilocybin itself is pharmacologically inactive — it is a prodrug. When ingested, intestinal alkaline phosphatases rapidly dephosphorylate psilocybin into psilocin (4-hydroxy-DMT), the compound responsible for all psychedelic effects. This conversion begins in the gut and is largely complete within 30-60 minutes, corresponding to the onset of noticeable effects. Psilocin then crosses the blood-brain barrier and binds to receptors throughout the central nervous system. Peak plasma psilocin concentrations occur approximately 80-100 minutes after oral ingestion and decline over 4-6 hours as the compound is metabolised primarily via monoamine oxidase and glucuronidation.
The speed of conversion and absorption is affected by digestive state (empty stomach accelerates onset), individual gut flora, and whether the mushroom material is consumed whole, as a tea, or in powdered capsule form.
Primary Mechanism: 5-HT2A Receptor Agonism
Psilocin's primary mechanism of action is partial agonism at serotonin (5-HT) receptors, with particularly high affinity for the 5-HT2A subtype. The 5-HT2A receptor is densely expressed in cortical regions including the prefrontal cortex, visual cortex, and association areas — regions critically involved in higher cognition, perception, and sense of self. This distribution explains why psychedelics produce profound alterations in consciousness and self-referential thinking while having minimal effects on motor function at typical doses.
The 5-HT2A receptor is a G-protein coupled receptor (GPCR) that, when activated, triggers intracellular signalling cascades involving phospholipase C, inositol triphosphate, and protein kinase C. These cascades alter the electrical excitability of pyramidal neurons in the cortex, disrupting the normal hierarchical processing of sensory information. Psilocin also shows partial agonism at 5-HT2C, 5-HT1A, and several other serotonin receptor subtypes — 5-HT1A activation, for instance, contributes to anxiolytic and mood-stabilising effects that partially balance the intensity of 5-HT2A stimulation.
Why 5-HT2A Activation Produces Psychedelic Effects
The prevailing model, supported by functional neuroimaging, is that 5-HT2A activation disrupts the normal "predictive coding" hierarchy of the brain. In ordinary consciousness, the brain constantly generates top-down predictions about incoming sensory data and suppresses what matches those predictions. Psychedelics — by activating 5-HT2A receptors in deep cortical layers — reduce the weight given to top-down predictions and amplify "prediction errors" (the mismatch signal). Sensory signals flood through without their normal filtering, producing heightened and distorted perception, and ordinary assumptions about reality and self become temporarily loosened.
Default Mode Network Suppression
One of the most consistent findings from neuroimaging studies of psilocybin is suppression of activity in the Default Mode Network (DMN). The DMN is a set of cortical regions — including the medial prefrontal cortex, posterior cingulate cortex, and angular gyrus — highly active during rest, mind-wandering, self-referential thought, and rumination. The DMN is strongly associated with the "narrative self" — the ongoing internal monologue that constructs a continuous sense of personal identity.
Robin Carhart-Harris and colleagues at Imperial College London first published fMRI evidence in 2012 demonstrating that intravenous psilocybin produced marked reductions in DMN BOLD signal, and that the degree of DMN suppression correlated directly with the subjective intensity of ego dissolution. Subsequent studies confirmed this with oral psilocybin at therapeutic doses. Psilocybin disrupts the normal anti-correlation between the DMN and task-positive networks, leading to unusual cross-network connectivity and the characteristic blending of internal and external experience.
Ego Dissolution and the DMN
At higher doses, DMN suppression can produce what researchers term "ego dissolution" — a transient loss of the felt boundary between self and world. This experience is hypothesised to be therapeutically valuable: it interrupts entrenched self-critical thought patterns, can produce a sense of psychological freedom, and may facilitate the "mystical-type" experience that predicts therapeutic outcome across multiple clinical trials.
Whole-Brain Connectivity: The Entropic Brain Hypothesis
Beyond DMN suppression, psilocybin produces a global increase in the complexity and entropy of brain activity. In ordinary waking consciousness, brain networks communicate in relatively predictable, modular patterns. Under psilocybin, these constraints are loosened: brain regions that do not normally communicate form transient connections, and the overall repertoire of brain states expands dramatically. Carhart-Harris proposed the "entropic brain hypothesis" — psychedelics temporarily shift the brain toward a higher-entropy state, more similar to dreaming or early childhood consciousness than to adult baseline, characterised by greater flexibility and reduced habitual patterning.
This increased global connectivity helps explain why psilocybin experiences are associated with synesthesia (cross-modal sensory blending), novel associations of ideas, and unusually vivid autobiographical memories — phenomena reflecting unusual communication between normally separate brain systems.
Neuroplasticity: Structural and Functional Changes
A major area of recent research concerns psilocybin's capacity to promote neuroplasticity — the ability of neurons to grow new connections and reorganise their activity patterns. This is particularly relevant to understanding how a single psilocybin session can produce therapeutic benefits lasting months.
Dendritic Spine Growth
A landmark 2021 paper by Cy Ly and colleagues in Cell Reports demonstrated that psilocin promotes rapid dendritic spine growth in cortical pyramidal neurons within 24 hours of administration in mouse models — an effect that persisted for at least one month. Dendritic spines are the tiny protrusions on neurons where synaptic connections form; their density reflects the richness of neural connectivity. Chronic stress and depression are associated with dendritic spine loss in the prefrontal cortex, so psilocybin's ability to reverse this pattern offers a compelling biological mechanism for its antidepressant effects.
BDNF and Synaptic Proteins
Psilocin also promotes the expression of brain-derived neurotrophic factor (BDNF) and TrkB receptor activation — a pathway shared with ketamine and rapid-acting antidepressants. BDNF supports neuronal survival, differentiation, and synaptic plasticity, and its levels are typically reduced in depression. Rapid BDNF upregulation following psilocybin may contribute to the fast onset and durability of antidepressant effects observed clinically.
Tolerance and Receptor Downregulation
Repeated use of psilocybin rapidly produces tolerance through 5-HT2A receptor downregulation — prolonged agonist exposure causes the receptor to be internalised and removed from the cell surface, reducing sensitivity. Tolerance to the subjective and perceptual effects develops within 2-3 days of daily use and is largely complete within a week. Cross-tolerance exists between psilocybin and other classic serotonergic psychedelics (LSD, DMT, mescaline) due to their shared receptor mechanism. Tolerance dissipates within approximately two weeks of abstinence. This rapid tolerance development explains why psilocybin is not considered addictive in the conventional sense — the reinforcement mechanism breaks down quickly with repeated use.
Drug Interactions and Contraindications
Because psilocin acts on serotonin receptors, combining it with other serotonergic substances creates meaningful risks. SSRIs compete with psilocin for 5-HT2A receptor binding and can significantly blunt the psychedelic response; chronic SSRI use may reduce psilocybin's therapeutic efficacy. Combining psilocybin with monoamine oxidase inhibitors (MAOIs) dramatically intensifies and prolongs effects, raising the risk of serotonin syndrome. Lithium combined with psilocybin is associated with an elevated risk of seizures based on case reports. These are among the primary contraindications in clinical trial screening protocols.
Amygdala Reactivity and Emotional Processing
In addition to cortical effects, psilocybin modulates activity in the amygdala — the brain's primary threat-detection and emotional memory centre. Human fMRI studies have found that psilocybin reduces amygdala reactivity to negative emotional stimuli compared with placebo. This reduced threat-salience may help explain the anxiolytic and antidepressant effects observed clinically. Importantly, the amygdala effect appears to persist beyond the acute session, contributing to the lasting reduction in anxiety and negative emotional bias observed in patients in the weeks following treatment.
Conclusion
Psilocybin's mechanisms of action are now understood at multiple levels — from receptor binding and intracellular signalling, through large-scale neural network reorganisation, to structural synaptic changes that persist long after the drug has been eliminated from the body. The core pharmacological action is 5-HT2A agonism by psilocin, which disrupts normal cortical filtering, suppresses the Default Mode Network, increases global brain entropy, and promotes neuroplasticity. These cascading effects produce the characteristic phenomenology of the psilocybin experience and appear to underlie the durable therapeutic benefits observed in clinical trials.
Emerging work on biased agonism may ultimately allow the development of compounds that retain therapeutic neuroplasticity-promoting effects without the full psychedelic experience — though whether the subjective experience itself is necessary for therapeutic benefit remains an open and actively debated question in the field.